CEO (Gene Therapy) XtRNA

The role

The CEO will lead the company's mission to transform RNA science into therapies for rare genetic diseases. You will guide the venture from research to clinical development, shape strategy, and drive fundraising.

What you will do

• Lead the company's overall strategy, growth, and fundraising, securing seed and Series A investment
• Drive the scientific and clinical roadmap in collaboration with the CSO toward IND readiness for the CMT2D program while expanding the broader tRNA platform
• Build and inspire a multidisciplinary team that combines scientific excellence with entrepreneurial focus
• Establish strong partnerships with investors, academic collaborators, pharmaceutical partners, and patient foundations
• Represent XtRNA Bio externally, communicating vision, progress, and potential to the biotech and investment communities

Required qualifications

• Advanced degree (PhD or MD) in Life Sciences, Biotechnology, Genetics, or a related field
• Proven experience in leading or scaling biotech or pharmaceutical ventures
• Demonstrated success in fundraising, including venture capital and strategic partnerships
• Proven track record in strategic transactions, including co-development partnerships, M&A, or successful exits with biotech or pharmaceutical companies
• Track record of translating early-stage scientific innovation into clinical development and tangible company value
• Strong scientific understanding of delivery technologies such as AAV capsids or related gene therapies and RNA biology and genetic disease mechanisms
• Familiarity with regulatory pathways, translational medicine, and early clinical development for rare diseases
• Entrepreneurial, hands-on, and comfortable operating in a dynamic, high-growth environment

Nice to have

• business training (MBA or equivalent) is an advantage
• ideally within RNA therapeutics, gene therapy, or rare disease

About the company

XtRNA Bio is a biotechnology company translating RNA biology into medicines to treat rare genetic diseases. It was founded in collaboration with NLC Health Ventures.